AbbVie sales and marketing update

AbbVie said FDA approved a 36,000 lipase-unit dose of Creon pancrelipase delayed-release capsules to treat pancreatic exocrine insufficiency (PEI). The product comprises a combination of porcine-derived lipases, proteases and amylases. The wholesale acquisition cost of the dose is $658.48 for 100 capsules and $1,611.89 for 250 capsules. The recommended doses for daily Creon vary with individual symptoms and diet. According to the company, this is the highest lipase dose available in the U.S. Creon is marketed in the U.S. and Japan, where it is known as Lipacreon. ...